Drug Profile
Research programme: cystic fibrosis therapy - Salus Therapeutics
Alternative Names: Antisense drug therapies research programme - Salus Therapeutics; Cystic fibrosis therapy research programme - Salus Therapeutics; Research programme: antisense drug therapies - Salus TherapeuticsLatest Information Update: 31 May 2006
Price :
$50
*
At a glance
- Originator Genta
- Developer Genta (CEASED)
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cystic fibrosis
Most Recent Events
- 13 Nov 2000 Preclinical development for Cystic fibrosis in USA (Unknown route)